Drug intelligence / Profile preview

Mycogone nigra

Development stage: Unknown
Lead developer: Greer Laboratories
Administration: Intradermal, Percutaneous, Subcutaneous

Overview

Mycogone nigra is a non-standardized allergenic extract derived from the fungus *Mycogone nigra*, used for the diagnosis and treatment of mold-related allergies. As a diagnostic tool, it is used in skin testing (percutaneous or intradermal) to identify immediate hypersensitivity (Type I) reactions. As a therapeutic agent, it is used in allergen immunotherapy (subcutaneous injections) to reduce clinical symptoms by inducing immunological tolerance. The extract contains a complex mixture of proteins and polysaccharides from the fungal source. It is manufactured by companies such as Greer Laboratories and is often included in multi-allergen mixes like Rinkel Mold Mix B.

Other names: Mycogone nigra extractMycogone nigra allergenic extract

Targets

IgE (Immunoglobulin E)

Beyond the preview

Go deeper on Mycogone nigra.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mycogone nigra.

Explore the full profile